UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): April 13, 2006
| |
|
|
| ALKERMES, INC. |
| (Exact Name of Registrant as Specified in its Charter) |
| |
| |
|
|
|
|
| PENNSYLVANIA |
|
1-14131 |
|
23-2472830 |
(State or Other Jurisdiction of
Incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.) |
| |
|
|
|
|
| |
|
|
| 88 Sidney Street |
|
|
| Cambridge,
Massachusetts |
|
02139 |
| (Address of principal executive offices)
|
|
(Zip Code) |
| |
|
|
Registrant’s telephone number, including area code: (617) 494-0171
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events
On April 13, 2006, Alkermes, Inc. issued a press release announcing that the U.S. Food and
Drug Administration (FDA) approved VIVITROLTM (naltrexone for extended-release
injectable suspension) for the treatment of alcohol dependence.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
| |
|
|
| Exhibit No. |
|
Description |
|
|
|
99.1
|
|
Press release issued by Alkermes, Inc. on April 13, 2006 |